RRx-001

RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity[1]. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α[2]. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity[3].

Product Specifications

CAS Number

[925206-65-1]

Product Name Alternative

Nibrozetone

UNSPSC

12352005

Hazard Statement

H301, H311, H331, H341

Target

Apoptosis; CD47; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/RRx-001.html

Concentration

10mM

Purity

99.79

Solubility

DMSO : ≥ 100 mg/mL

Smiles

BrCC(N1CC([N+]([O-])=O)([N+]([O-])=O)C1)=O

Molecular Formula

C5H6BrN3O5

Molecular Weight

268.02

Precautions

H301, H311, H331, H341

References & Citations

[1]Das DS, et al. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 Nov;30 (11) :2187-2197.|[2]Cabrales P, et al. RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages. Transl Oncol. 2019 Apr;12 (4) :626-632.|[3]Yalcin O, et al. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malar J. 2015 May 28;14:218.